Sang Hun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sang Hun Lee has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jeong Woo Park
School of Biological Sciences, University of Ulsan, Ulsan, Korea
4 shared publications - Seong Cheol Kim
Basic-Clinic Convergence Research Institute, University of Ulsan, Ulsan, Korea
4 shared publications - Sungchan Park
Basic-Clinic Convergence Research Institute, University of Ulsan, Ulsan, Korea
4 shared publications - Won Hyeok Lee
Basic-Clinic Convergence Research Institute, University of Ulsan, Ulsan, Korea
4 shared publications - Ji Hyung Yoon
Basic-Clinic Convergence Research Institute, University of Ulsan, Ulsan, Korea
3 shared publications - Kyung Hyun Moon
Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Dipeptidyl Peptidase-4 Inhibitor Enhances the Efficacy of Docetaxel via Adenosine Triphosphate Depletion and Modulation of Mitochondrial Fusion-Fission in Castration-Resistant Prostate Cancer
Lee WH, et al. World J Mens Health. 2026 ;44:e85. https://doi.org/10.5534/wjmh.260048
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessDipeptidyl Peptidase-4 Inhibitor Enhances the Efficacy of Docetaxel via Adenosine Triphosphate Depletion and Modulation of Mitochondrial Fusion-Fission in Castration-Resistant Prostate Cancer
Lee WH, et al. World J Mens Health. 2026 ;44:e85. https://doi.org/10.5534/wjmh.260048
- Open Access
- 1 January 2025
- Published by XMLink in Investigative and Clinical Urology
- Vol. 66 (1) , 56-66
DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
Lee JM, et al. Investig Clin Urol. 2025 Jan;66(1):56-66. https://doi.org/10.4111/icu.20240263
- 1 January 2025
- Published by XMLink in Investigative and Clinical Urology
- Vol. 66 (1) , 56-66
Open AccessDRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
Lee JM, et al. Investig Clin Urol. 2025 Jan;66(1):56-66. https://doi.org/10.4111/icu.20240263
- Open Access
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (3) , 649-658
Docetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2
Lee WH, et al. World J Mens Health. 2023 Jan;41:e2. https://doi.org/10.5534/wjmh.220073
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (3) , 649-658
Open AccessDocetaxel Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer Cells via Epigenetic Gene Regulation by Enhancer of Zeste Homolog 2
Lee WH, et al. World J Mens Health. 2023 Jan;41:e2. https://doi.org/10.5534/wjmh.220073
- Open Access
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (4) , 485-495
Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis
Kim SC, et al. Investig Clin Urol. 2021 Jul;62(4):485-495. https://doi.org/10.4111/icu.20200574
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (4) , 485-495
Open AccessDevelopmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis
Kim SC, et al. Investig Clin Urol. 2021 Jul;62(4):485-495. https://doi.org/10.4111/icu.20200574